

Lok Lam Ngai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7645344/publications.pdf>

Version: 2024-02-01

12
papers

656
citations

1040056

9
h-index

1199594

12
g-index

12
all docs

12
docs citations

12
times ranked

638
citing authors

#	ARTICLE	IF	CITATIONS
1	2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. <i>Blood</i> , 2021, 138, 2753-2767.	1.4	305
2	The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw166.	6.3	88
3	Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations. <i>Leukemia</i> , 2021, 35, 1529-1538.	7.2	48
4	Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 439-456.	5.9	39
5	MRD Tailored Therapy in AML: What We Have Learned So Far. <i>Frontiers in Oncology</i> , 2020, 10, 603636.	2.8	39
6	The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis. <i>Gastric Cancer</i> , 2016, 19, 696-712.	5.3	35
7	Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party. <i>HemaSphere</i> , 2022, 6, e676.	2.7	35
8	Quality of Life During Palliative Systemic Therapy for Esophagogastric Cancer: Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 12-29.	6.3	25
9	Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis. <i>Scientific Reports</i> , 2017, 7, 7142.	3.3	20
10	TOXview: a novel graphical presentation of cancer treatment toxicity profiles. <i>Acta Oncologica</i> , 2019, 58, 1138-1148.	1.8	9
11	Early assessment of clofarabine effectiveness based on measurable residual disease, including AML stem cells. <i>Blood</i> , 2021, 137, 1694-1697.	1.4	8
12	Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients. <i>European Journal of Haematology</i> , 2021, 107, 343-353.	2.2	5